News Biocon Limited

Equities

BIOCON

INE376G01013

Delayed NSE India S.E. Other stock markets 02:21:00 2024-04-19 am EDT			5-day change	1st Jan Change
262.4 ^INR	-1.80%		-4.29%	+5.05%

Apr. 18	India's Biocon developing its own version of Wegovy, clinical trial likely next year	RE
Apr. 18	Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

India's Biocon developing its own version of Wegovy, clinical trial likely next year	Apr. 18	RE
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	Apr. 17	MT
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	Apr. 17	CI
Biocon Board to Consider Dividend for Fiscal 2024	Apr. 10	MT
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	Apr. 02	MT
Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	Mar. 31	CI
Biocon is the first generics company to obtain approval for diabetes drug, Liraglutide, in the U.K.	Mar. 28	AQ
Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K	Mar. 27	CI
Updates On Aflibercept BPCIA Litigation	Mar. 26	AQ
Biocon Limited Receives an Order from the Reserve Bank of India	Mar. 22	CI
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	Mar. 15	MT
Biocon's CFO Resigns	Mar. 14	MT
Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer	Mar. 14	CI
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	Mar. 14	MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	Mar. 14	RE
Biocon Limited Announces Executive Appointments	Mar. 04	CI
Biocon Arm to Launch Colorectal Cancer Biosimilar in Canada	Mar. 04	MT
Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara	Mar. 01	AQ
PTAB Institutes Celltrion And Biocon IPRs On Regeneron Aflibercept Dosing Patent	Feb. 29	AQ
Bristol Myers CEO says India to have largest R&D presence outside US by 2025	Feb. 27	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biocon Limited

Equities

BIOCON

INE376G01013

Summary

Filters